Provided by Tiger Trade Technology Pte. Ltd.

Capricor Therapeutics

26.86
-1.0700-3.83%
Volume:676.41K
Turnover:18.22M
Market Cap:1.39B
PE:-14.88
High:27.63
Open:26.69
Low:26.30
Close:27.93
52wk High:40.37
52wk Low:4.30
Shares:51.72M
Float Shares:46.19M
Volume Ratio:0.81
T/O Rate:1.46%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.8055
EPS(LYR):-1.1490
ROE:-107.79%
ROA:-49.39%
PB:16.56
PE(LYR):-23.38

Loading ...

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Nov 07, 2025

Capricor Therapeutics announces publication in Biomedicines on Deramiocel

TIPRANKS
·
Nov 03, 2025

Capricor Therapeutics to Present Third Quarter 2025 Financial Results and Recent Corporate Update on November 10

GlobeNewswire
·
Oct 31, 2025

Capricor Therapeutics Inc. Releases Investor Presentation Highlighting Progress in Duchenne Muscular Dystrophy Program and Exosome Platform Development

Reuters
·
Oct 13, 2025

Capricor Therapeutics management to meet with Piper Sandler

TIPRANKS
·
Oct 08, 2025

Capricor Therapeutics’ Deramiocel Progress and FDA Clarity Underpin Buy Rating

TIPRANKS
·
Sep 27, 2025

Capricor Therapeutics Price Target Maintained With a $24.00/Share by HC Wainwright & Co.

Dow Jones
·
Sep 25, 2025

Optimistic Buy Rating for Capricor Therapeutics Driven by Regulatory Progress and Strategic Positioning

TIPRANKS
·
Sep 25, 2025

Capricor Therapeutics Shares Rise After Positive Type A Meeting With FDA

Dow Jones
·
Sep 25, 2025

Capricor approval on track for mid-2026, says JonesResearch

TIPRANKS
·
Sep 25, 2025

Unusually active option classes on open September 25th

TIPRANKS
·
Sep 25, 2025

BUZZ-Capricor climbs as FDA clears path for resubmission of cell therapy application

Reuters
·
Sep 25, 2025

Capricor to submit HOPE-3 data with complete response to FDA CRL

TIPRANKS
·
Sep 25, 2025

Capricor Therapeutics Inc - Company to Resubmit Crl Response Under Current Bla

THOMSON REUTERS
·
Sep 25, 2025

Capricor Therapeutics Inc - FDA and Capricor Align on Hope-3 Trial Endpoints

THOMSON REUTERS
·
Sep 25, 2025

Capricor Therapeutics Provides Regulatory Update on Deramiocel Program for Duchenne Muscular Dystrophy Following Type A Meeting

GlobeNewswire
·
Sep 25, 2025

Capricor Therapeutics: Positive Outlook Amid FDA Discussions and Efficacy Demonstrations in DMD Treatment

TIPRANKS
·
Sep 17, 2025

Capricor Therapeutics Faces Class Action Lawsuit Over Alleged Securities Fraud, Investors Report Financial Losses

Reuters
·
Sep 15, 2025

Capricor Therapeutics Price Target Maintained With a $24.00/Share by HC Wainwright & Co.

Dow Jones
·
Sep 11, 2025

Optimistic Buy Rating for Capricor Therapeutics Amid Regulatory and Clinical Advancements

TIPRANKS
·
Sep 11, 2025